Structural study of anthrax yields new antibiotic target

January 28, 2008
Structural study of anthrax yields new antibiotic target
Anthrax attack. The anthrax UDP-GlcNAc 2-epimerase enzyme uses two binding sites (colored sections, above) to interact with its substrate molecules. One of those sites isn’t found in mammalian cells, and presents an attractive target for drug design. Credit: Rockefeller University

Researchers studying anthrax knew they were onto something when they discovered an opponent the bacterium couldn’t outwit. Probing a bit deeper, they discovered this was because the attacker was interacting with something anthrax requires to survive: a carbohydrate in its cell wall. Now, in a study that has implications for the development of a new class of antibiotics, Rockefeller scientists report that they’ve determined the structure of an enzyme involved in the pathway responsible for building this essential carbohydrate.

The research stems from a collaboration between structural biologist C. Erec Stebbins and bacteriologist Vincent Fischetti, and is published online in EMBO reports. The scientists not only describe the crystal structure of an enzyme involved in this vulnerable cell-wall pathway, they were able to use that structure to determine how the enzyme is regulated. And because the mammalian form of this enzyme is slightly different than the anthrax form, the researchers propose that it should be possible to inhibit its activity in bacteria without causing collateral damage to mammalian cells.

“These enzymes have a unique mode of regulation that’s actually going to tie into the idea of drug development,” says Stebbins, head of the Laboratory of Structural Microbiology. By creating a crystal structure of the enzyme with its substrate attached, he found that the enzyme’s activity is regulated by the very molecules it acts upon.

“So if we could bind a small molecule to the binding site in such a way that it doesn’t productively activate it, we could inhibit the activity of the molecule without inhibiting the same active site of mammalian enzymes,” Stebbins says. This, he hopes, would result in bacteria that are unable to build their cell walls and therefore would be unable to survive.

The anthrax bacterium has two copies of the gene responsible for producing this enzyme. To examine its potential as a drug target, Fischetti — head of the Laboratory of Bacterial Pathogenesis and Immunology — and his lab created a version of the bacterium with one of these genes knocked out. The resulting mutants grew much, much more slowly, Stebbins says, which tells them that if they could come up with an inhibitor, “it would probably hit these things hard.”

Also promising is that the same inhibitor site exists in a number of related bacteria, including those that cause staphylococcal infections and pneumonia. So if researchers could devise a drug that targets this site, it might be versatile enough to act against a range of bacteria. “It’s still in the very early stages,” Stebbins says, “but the structure gave us a very interesting idea for how we might tailor our drug search.”

Link: www.nature.com/embor/journal/vaop/ncurrent/abs/7401154.html

Source: Rockefeller University

Explore further: Chemists recruit anthrax to deliver cancer drugs

Related Stories

Chemists recruit anthrax to deliver cancer drugs

September 25, 2014

Bacillus anthracis bacteria have very efficient machinery for injecting toxic proteins into cells, leading to the potentially deadly infection known as anthrax. A team of MIT researchers has now hijacked that delivery system ...

Toxic injection with elastic band

February 24, 2014

Bacteria have developed many different ways of smuggling their toxic cargo into cells. Tripartite Tc toxin complexes, which are used by bacteria like the plague pathogen Yersinia pestis and the insect pathogen Photorhabdus ...

Milestone in fight against deadly disease

December 7, 2010

Scientists at Seattle Biomedical Research Institute (Seattle BioMed) and Northwestern University Feinberg School of Medicine have reached a major milestone in the effort to wipe out some of the most lethal diseases on the ...

How do we kill rogue cells? Assassin's tricks revealed

October 31, 2010

A team of Melbourne and London researchers have shown how a protein called perforin punches holes in, and kills, rogue cells in our bodies. Their discovery of the mechanism of this assassin is published today in the science ...

Recommended for you

A cataclysmic event of a certain age

July 27, 2015

At the end of the Pleistocene period, approximately 12,800 years ago—give or take a few centuries—a cosmic impact triggered an abrupt cooling episode that earth scientists refer to as the Younger Dryas.

New blow for 'supersymmetry' physics theory

July 27, 2015

In a new blow for the futuristic "supersymmetry" theory of the universe's basic anatomy, experts reported fresh evidence Monday of subatomic activity consistent with the mainstream Standard Model of particle physics.

Dense star clusters shown to be binary black hole factories

July 29, 2015

The coalescence of two black holes—a very violent and exotic event—is one of the most sought-after observations of modern astronomy. But, as these mergers emit no light of any kind, finding such elusive events has been ...

Image: Hubble sees a dying star's final moments

July 31, 2015

A dying star's final moments are captured in this image from the NASA/ESA Hubble Space Telescope. The death throes of this star may only last mere moments on a cosmological timescale, but this star's demise is still quite ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.